7,500 Shares, Again and Again

7,500 Shares, Again and Again

Robert Blum, the chief executive of Cytokinetics, sold 7,500 shares of his company's stock on August 10 for about $576,000. The weird part sits right next to it: he also sold 7,500 shares in April, and 7,500 in June, and 7,500 in July. The price was different every time — $66.63, $70.46, $80.87, $76.76 — and the quantity never moved. A human being with an opinion about the stock does not sell the same amount at four different prices. A machine does.

That machine is why this story is news, and also why it contains no information at all. Insider selling is one of the few financial genres where the market built the machinery specifically to remove the content. The CEO is the person in a public company least allowed to trade on material nonpublic information and most likely to be suspected of it, so the standard solution — a Rule 10b5-1 trading plan, the safe harbor most serious insider selling now runs through — is a contract designed to make the sale a non-signal. You adopt the written plan while you can still sincerely say you know nothing, hand the keys to a broker, and let the plan sell fixed amounts on fixed dates. The SEC rewrote the rules in 2022, including a mandatory cooling-off period between plan adoption and the first sale, largely because people kept finding ways to make the plans behave as though they were based on knowledge after all.

What the plan is doing here

The recent filings say plainly that this is a plan, and the plan is doing something specific. Blum has old options struck at $10.60; each installment, he exercises 7,500 of them and sells the same 7,500 shares at whatever the market offers that day. In July the market offered $80.87; in August, $76.76; the block was identical. He is a man who ran a long bet on a heart-drug program converting that bet into cash, on autopilot, netting roughly $66 a share each time the plan fires. None of this is a wager on the stock's direction: the quantity and the dates were fixed before the prices were known, and the sales kept coming through both the run and the pullback. You cannot tell from any of these trades whether Blum thinks Cytokinetics is expensive or cheap, which is the entire design.

The size is its own tell. The August sale brought $575,700; afterward Blum still directly held 377,820 shares, worth about $29 million at the current price, with 171,745 more options in the drawer — another $11 million or so of upside if the stock simply stays where it is. The August sale was about 2% of his direct stake. This is not an insider sprinting for the exit. It is a compensation calendar.

Why it looks like news anyway

Cytokinetics is a good place to get this question, because it is exactly the setup where the scary read feels most reasonable. The stock more than doubled over the past year, to a 52-week high just over $88, after the FDA approved aficamten — the company's drug for obstructive hypertrophic cardiomyopathy — in December 2025. It has since slipped to around $77, down about 13% from the top. So the ingredients are all there: the boss selling into a post-run pullback, near the peak of a good story. If you read the headline frame — "CEO sells $576,000 of stock" — this is the moment to feel informed. If you read the machine — a plan that sells on schedule regardless of price — you are watching a payroll deduction running in reverse.

Reader: The CEO is selling at the top; he must know something. Company: He contractually agreed not to know anything, in advance, in writing, and the plan chose the dates.

Plans are not magic, and the 2022 rulemaking was substantially about the fact that they get gamed — insiders adopt them and quietly kill them, and the shield has been used as a disguise. A plan proves a sale was scheduled; it does not prove the scheduler is permanently clueless. But even the most suspicious reading has to hold onto the same fact here: a fixed 7,500-share block every few weeks, converting one old grant, is not the shape of informed selling. It is the shape of compensation turning paper into cash on autopilot. If Blum had something to trade on, the July sale would not have to match the June sale exactly.

The bigger seller

And for scale, keep straight what actually is being sold: the four sales since April sum to about $2.2 million, while Cytokinetics itself sold $805 million of new stock in a May offering. If equity selling were information, the number that would matter would be the company's, not the CEO's. Both, in the end, are just how a drug company on a commercial launch and its executives get liquid. On the latest session the flows were small and roughly balanced in every bucket — retail mildly net buyers, large orders mildly net sellers — which is the market's way of noting and dismissing the drip.

The mild comedy of the genre is that every insider-sale headline poses a question the seller has been legally engineered not to answer. Blum turned $10.60 options into $76.76 cash, on schedule, without anyone able to say he knew anything; the news wires got the headline; the reader got a puzzle with no answer key. The label says "insider transaction." The reality is a standing order. When a CEO sells stock this way, the correct reading is not that he knows something; it is that a plan that predates any knowledge is running on time.